長春高新(000661.SZ):子公司凍幹人用狂犬病疫苗(人二倍體細胞)臨牀試驗申請獲得批准
格隆匯12月6日丨長春高新(000661.SZ)公佈,近日,長春高新技術產業(集團)股份有限公司子公司長春百克生物科技股份公司(簡稱“百克生物”)收到國家藥品監督管理局核准簽發的《藥物臨牀試驗批准通知書》,同意百克生物申報的凍幹人用狂犬病疫苗(人二倍體細胞)開展預防狂犬病的臨牀試驗。
本次百克生物獲批的凍幹人用狂犬病疫苗(人二倍體細胞)系採用國際上廣泛用於疫苗生產的人二倍體細胞,具有免疫原性好、起效速率快、安全性好、免疫持續時間長等優勢,尤其適用於過敏體質者、老人及兒童等免疫力偏低下的人羣。凍幹人用狂犬病疫苗(人二倍體細胞)以其差異化優勢,在豐富公司在研產品梯隊的同時,更大程度的滿足市場需求。若該品種順利完成臨牀試驗並獲批上市,有助於公司優化產品結構、產業佈局和主營業務的全面發展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.